Stereotaxis (NYSEAMERICAN:STXS) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Stereotaxis (NYSEAMERICAN:STXS) posted its earnings results on Tuesday. The company reported ($0.06) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.01), FiscalAI reports. Stereotaxis had a negative return on equity of 291.99% and a negative net margin of 66.85%.The firm had revenue of $6.29 million for the quarter, compared to analysts’ expectations of $8.50 million.

Stereotaxis Price Performance

Stereotaxis stock traded up $0.04 during midday trading on Tuesday, reaching $1.92. The company had a trading volume of 373,244 shares, compared to its average volume of 474,527. The company has a market capitalization of $187.16 million, a P/E ratio of -7.68 and a beta of 1.34. Stereotaxis has a 12-month low of $1.74 and a 12-month high of $3.59. The firm’s fifty day simple moving average is $1.93 and its 200-day simple moving average is $2.26.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the stock. WealthPLAN Partners LLC purchased a new position in Stereotaxis in the 4th quarter valued at about $29,000. BNP Paribas Financial Markets lifted its stake in Stereotaxis by 106.5% in the 3rd quarter. BNP Paribas Financial Markets now owns 11,461 shares of the company’s stock valued at $36,000 after buying an additional 5,910 shares in the last quarter. Schonfeld Strategic Advisors LLC purchased a new position in Stereotaxis in the 3rd quarter valued at about $38,000. HRT Financial LP purchased a new position in Stereotaxis in the 4th quarter valued at about $42,000. Finally, Moneta Group Investment Advisors LLC acquired a new stake in Stereotaxis in the 3rd quarter valued at about $43,000. 45.35% of the stock is owned by hedge funds and other institutional investors.

Stereotaxis Company Profile

Stereotaxis, Inc is a medical device company that develops and commercializes robotic magnetic navigation systems for use in electrophysiology procedures. Its core technology leverages precisely controlled magnetic fields to guide ultra-thin, magnetically enabled catheters through the vascular system, allowing physicians to perform complex cardiac ablation and diagnostic procedures with enhanced precision and stability. This platform aims to reduce procedure times and radiation exposure for both patients and clinical staff.

The company’s flagship offering, the Niobe Magnetic Navigation System, integrates with a variety of catheter types and electrophysiology mapping systems to support treatment of arrhythmias such as atrial fibrillation and ventricular tachycardia.